Understanding How CMS Will Track Antipsychotic Use In Nursing Homes - Part I

We unpack how CMS will monitor antipsychotic use in nursing homes, why the national average is changing, and what datasets will be cross-checked to produce public quality measures. We set the stage for part two, where we dig into practical steps to strengthen documentation, data integrity, and care processes.

• OIG findings and the CMS refocus
• reasons for increased oversight and risk signals
• how MDS and claims will be cross-referenced
• shift in national average to 16.98%
• implications for star ratings and care compare
• focus on accurate capture, verification, and data integrity
• preview of nuts-and-bolts actions in part two

Please feel free to reach out to Verity Consulting at Verity Team.com if you'd like further assistance with your healthcare compliance needs